David A. Lombardi
Harvard University
H-index: 39
North America-United States
Top articles of David A. Lombardi
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow | Canadian Respiratory Journal | Jill A Ohar Donald A Mahler Gabrielle N Davis David A Lombardi Edmund J Moran | 2024/3/22 |
Post hoc analysis of lung function improvement and patient-reported outcomes with revefenacin in adults with moderate-to-very severe COPD and comorbid anxiety or depression | Chronic Obstr Pulm Dis | AM Yohannes AS Iyer C Clay | 2024 |
Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease | Respiratory Medicine | James F Donohue Gary T Ferguson Jill A Ohar David A Lombardi Roslyn F Schneider | 2023/3/1 |
Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial | BMJ Open Respiratory Research | John Belperio Tuan Nguyen David A Lombardi Maxim Bogus Valentyn Moskalenko | 2023/7/1 |
Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial | JAMA Network Open | Matthew D Sims Sahil Khanna Paul Feuerstadt Thomas J Louie Colleen R Kelly | 2023/2/1 |
Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection | Antimicrobial Stewardship & Healthcare Epidemiology | Matthew Sims Michael Silverman Thomas Louie Elaine Wang Colleen Kraft | 2023/6 |
Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l | 2023/1/26 | ||
Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI | Antimicrobial Stewardship & Healthcare Epidemiology | Matthew Sims Charles Berenson Stuart Cohen Elaine Wang Elizabeth Hohmann | 2023/6 |
An Integrated Safety and Efficacy Analysis of Phase 3 ECOSPOR III and ECOSPOR IV Studies of Fecal Microbiota Spores, live-brpk (Vost TM; VOS; Formerly SER-109) in Recurrent … | Anne J Gonzales-Luna Matthew D Sims David A Lombardi Lisa von Moltke Sissi V Pham | 2023 | |
Su1873 RESULTS FROM AN OPEN-LABEL STUDY (ECOSPOR IV) TO EVALUATE THE SAFETY AND EFFICACY OF SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN ADULTS WITH RECURRENT … | Gastroenterology | Darrell S Pardi Caterina Oneto Charles Berenson Mayur Ramesh Aasim M Sheikh | 2023/5/1 |
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based … | Clinical Infectious Diseases | Charles S Berenson Bret Lashner Louis Y Korman Elizabeth Hohmann Abhishek Deshpande | 2023/12/1 |
694 DURABILITY OF THE CLINICAL RESPONSE TO SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN A PHASE 3 OPEN-LABEL TRIAL (ECOSPOR IV) IN PATIENTS WITH RECURRENT … | Gastroenterology | Edward S Huang Bret Lashner Matthew Sims Bharat Misra Huy Tran | 2023/5/1 |
S176 Health-Related Quality of Life With Fecal Microbiota Spores, Live (Formerly SER-109), an Oral Microbiota Therapeutic for Recurrent Clostridioides Difficile Infection … | Official journal of the American College of Gastroenterology| ACG | Anne J Gonzales-Luna Barbara McGovern David A Lombardi Lisa von Moltke Dina Hot | 2023/10/1 |
Chronotypes in the US: Influence of longitude position in a time zone | Chronobiology International | Dorothee Fischer David A Lombardi | 2022/3/4 |
POST HOC ANALYSIS OF PATIENT-REPORTED OUTCOMES WITH REVEFENACIN IN ADULTS WITH MODERATE TO VERY SEVERE COPD AND COMORBID ANXIETY OR DEPRESSION | Chest | Abebaw M Yohannes Anand S Iyer Candice Clay Lauren Cochran Xianyi Chen | 2022/10/1 |
Fixed point theorem for multivalued non-self mappings satisfying JS-contraction with an application | Ural Mathematical Journal | Aron David Kumar Santosh | 2022 |
Outcomes of a phase 2 trial for the inhaled JAK inhibitor, nezulcitinib, in hospitalized patients with acute lung injury due to severe COVID-19 | R Saggar D Singh E Moran D Lombardi T Nguyen | 2022/9/4 | |
An Open-Label Study (ECOSPOR IV) to Evaluate the Safety, Efficacy and Durability of SER-109, an Investigational Oral Microbiome Therapeutic, in Adults With Recurrent … | The American Journal of Gastroenterology | Paul Feuerstadt Edward Huang Caterina Oneto Darrell S Pardi Elaine E Wang | 2022 |
Efficacy and safety of SER-109, an investigational microbiome therapeutic for recurrent clostridioides difficile infection: Data from ECOSPOR III, a phase 3 … | Alla Paskovaty Charles S Berenson Thomas J Louie Elaine Wang David A Lombardi | 2022/6/1 | |
The safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor: results from part C of a first-in-human study in participants with moderate to … | Am J Respir Crit Care Med | Nathan D Pfeifer Tuan Nguyen David A Lombardi Kenneth Colley Wayne Yates | 2022/5/1 |
Co-Authors
